Alexion Pharmaceuticals, Inc.

Company Information

Company Name
Alexion Pharmaceuticals, Inc.
Address
352 Knotter Drive
Cheshire, CT, 06410
Phone
1 203-271-8221
URL
n/a
DUNS
n/a
Number of Employees
n/a
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N

Award Totals

PROGRAM/PHASE
AWARD AMOUNT ($)
NUMBER OF AWARDS
SBIR Phase I
$1,035,396.00
6
SBIR Phase II
$734,816.00
1
Chart code to be here

Award List

  1. Somatic Cell Gene Therapy for Hemophilia B

    Amount: $74,636.00

    Blood coagulation factor IX is absent or deficient in hemophilia B patients. Current therapy, thetransfusion of human whole blood components, is effective, but it is not prophylactic or free of risk.O ...

    SBIR Phase I 1994 Department of Health and Human Services
  2. Complement Activation and the Platelet Storage Le

    Amount: $734,816.00

    We will systematically examine whether complement activation plays a significant role in theplatelet storage lesion (PSL). The goals of the project are four-fold: (1) to assess the etiology of PSL byd ...

    SBIR Phase II 1995 Department of Health and Human Services
  3. Generation of Complement Resistant Retroviral Vectors

    Amount: $100,000.00

    The inactivation of retroviral vectors derived from murine cells in human serum represents a formidmany potential applications of in vivo retroviral-mediated gene therapy. We have recently demonstrato ...

    SBIR Phase I 1995 Department of Health and Human Services
  4. COMPLEMENT ACTIVATION AND MYOCARDIAL INFARCTION

    Amount: $93,760.00

    Coronary artery disease is associated with extensive morbidity and mortality as well as substantial financial cost. An estimated 11.2 million people in the USA have coronary artery disease that leads ...

    SBIR Phase I 1997 Department of Health and Human Services
  5. N/A

    Amount: $100,000.00

    N/A

    SBIR Phase I 2000 Department of Health and Human Services
  6. Nebulizing Eculizumab for intrapulmonary C5 inhibition

    Amount: $592,000.00

    DESCRIPTION (provided by applicant): The complement component C5 is common to all three pathways of complement activation. Its involvement in the pathogenesis of asthma is controversial. We have recen ...

    SBIR Phase I 2005 Department of Health and Human Services
  7. Complement Activation and the Platelet Storage Le

    Amount: $75,000.00

    N/A

    SBIR Phase I 1994 Department of Health and Human Services

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government